Premier Statement on Trump’s Executive Order on Restoring a Robust Domestic Manufacturing Base for Prescription Drugs

By Soumi Saha, Premier Senior Vice President, Government Affairs, Premier Inc.

Today's Executive Order signals growing momentum behind a goal Premier has been spotlighting for years: strengthening the healthcare supply chain starts with prioritizing domestic manufacturing.

Premier has consistently called for a comprehensive approach-including accelerating Food and Drug Administration (FDA) approvals for U.S.-based facilities that manufacture critical drugs and medical supplies. The protracted timeline for bringing a new domestic facility online and retooling an existing one is incompatible with the urgent public health challenges we face. Creating an expedited pathway for domestically manufactured products is a critical step toward building a more resilient, responsive and secure healthcare supply chain.

But this can't be a one-policy solution. Real resilience is built like a braided rope-stronger with multiple strands. As we told the Department of Commerce today, alongside faster approvals, we need targeted tax incentives, fair reimbursement and trusted trade partnerships for near-shoring. Only with this kind of multi-pronged strategy can we build the strong domestic foundation our healthcare system-and patients-deserve.